• Mashup Score: 1

    In this edition of The Journal of Rheumatology , I will be bringing to your attention the following 6 articles from the 2010s that had, and continue to have, a significant impact in rheumatology. Although I usually choose 3 papers, I have chosen 6 that can be grouped into 3 categories. The first category has a single paper that describes a modification of the American College of Rheumatology (ACR) classification of fibromyalgia (FM),1 the second category contains 2 papers on the use of the internet and social media in rheumatology,2,3 and the third contains 3 papers on long-term outcome studies in rheumatoid arthritis (RA).4-6 The first paper I wish to bring to your attention is “Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia” by Wolfe et al. … Address correspondence to Dr. E.D. Silverman, Editor-in-Chief, The Journal of Rheumatology, 365 Bloor Street East, Suite 901, Toronto

    Tweet Tweets with this article
    • 50th Volume Reprint Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies 📰 https://t.co/WlKRndLtfO #tofacitinib #rheumatoidarthritis https://t.co/xQ8DBs69id

  • Mashup Score: 0

    Objective To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis. Methods Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirheumatic drugs were randomly divided into two groups at baseline, and tofacitinib treatment in combination with MTX was administered to both groups….

    Tweet Tweets with this article
    • open-label randomised study in #RA patients and inadequate #MTX response receiving #tofacitinib addon -48/113 in remission at week 52 then stop either tofa or MTX At week 104: 7/24 with tofa stop remain remission 10/20 with MTX stop remain in remission https://t.co/AgI6oUyWnn https://t.co/qAITxuB6T2

  • Mashup Score: 0

    At month 3, patients treated with tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males.

    Tweet Tweets with this article
    • At month 3, patients treated with #tofacitinib achieved higher rates of ACR20/50, MDA, and PASI75 in both sexes when compared with the placebo. However, female patients were less likely to achieve MDA when compared with males. https://t.co/quIzDv1qtt #PsoriaticArthritis

  • Mashup Score: 0

    Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology. “Dactylitis is considered a core domain of musculoskeletal symptoms in PsA and is important for both patients and physicians when developing treatment strategies,”

    Tweet Tweets with this article
    • ICYMI: Patients with psoriatic #arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive #tofacitinib https://t.co/S5VK5SD0bH

  • Mashup Score: 0

    Patients with psoriatic arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive tofacitinib, according to data published in BMC Rheumatology. “Dactylitis is considered a core domain of musculoskeletal symptoms in PsA and is important for both patients and physicians when developing treatment strategies,”

    Tweet Tweets with this article
    • Patients with psoriatic #arthritis who receive tofacitinib demonstrate “sustained improvements” in dactylitis compared with those who did not receive #tofacitinib https://t.co/S5VK5SD0bH